Calm vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calm is a leading mental wellness app offering sleep, meditation, and relaxation content with enterprise health benefits programs serving over 100 million downloads.
About
Calm is a digital mental health company founded in 2012 by Michael Acton Smith and Alex Tew that has grown into one of the most downloaded and highest-grossing health apps globally. The platform offers guided meditations, sleep stories narrated by celebrities, breathing exercises, and relaxing music designed to reduce stress, improve sleep quality, and support overall mental wellness. Calm has exceeded 100 million downloads and reached a $2B valuation with backing from TPG, making it one of the most valuable standalone consumer wellness applications. The company has expanded into enterprise with Calm Business, providing employee mental health and wellbeing benefits to thousands of organizations. Calm has invested heavily in content production, partnering with prominent voices including LeBron James, Matthew McConaughey, and Harry Styles for exclusive audio content. The company also offers Calm Kids with age-appropriate mindfulness content for children. While positioned primarily as a consumer wellness tool rather than a clinical platform, Calm's scale and brand recognition have made it a leading solution for companies seeking accessible, low-friction mental wellness benefits for large employee populations.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.